FasterCures adds innovation experts as senior fellows
FasterCures is expanding its work by adding two highly respected innovators – biopharmaceutical industry expert Bernard Munos and open science leader John Wilbanks – as senior fellows. Munos and Wilbanks will work on projects that will help FasterCures build consensus around innovative solutions to important public policy challenges in the life sciences industry and medical research and development ecosystem. Munos will focus on trends in the biopharmaceutical industry that enable or curtail innovation, while Wilbanks will spotlight how open science and data-driven initiatives are paving a more effective path toward therapies.
FasterCures Program Updates
Our goal: Improve research processes and develop policies that will better support efficient development and approval of new therapies.
Briefing focuses on importance of translating discoveries into cures
FasterCures hosted more than 100 Congressional staffers, patient advocates, academics, and drug developers at a Capitol Hill briefing about the importance of federal support for translational research, the phase of medical R&D between the birth of a basic scientific discovery made in the lab and when a pharmaceutical company tests out a potential new therapy with patients. The briefing featured opening remarks from House Majority Leader Eric Cantor, and a panel of Chris Austin of the National Center for Advancing Translational Sciences (NCATS), Francis Collins of the National Institutes of Health (NIH), Simeon Taylor of Bristol-Myers Squibb, Sharon Terry of Genetic Alliance, and moderated by Margaret Anderson of FasterCures.
How investing in the Human Genome Project led to $1 trillion return
United for Medical Research and Battelle released a report, "The Impact of Genomics on the U.S. Economy," that showed every $1 invested in the Human Genome Project has triggered $178 in U.S. economic activity. Check out our blog on the report and a Capitol Hill briefing that featured NIH Director Francis Collins. FasterCures is a member of United for Medical Research.
Our goal: Stimulate innovative collaborations across all sectors – academia, government, industry, investors, and nonprofits – to speed up the time it takes to get new therapies from the lab to patients.
Apply now to present your innovative collaboration at Partnering for Cures
Apply by July 31 to present your innovative, cross-sector collaboration at Partnering for Cures, where you will have an opportunity to engage potential investors, partners, and collaborators in moving your existing initiative forward or amplifying the impact of your approach. And registration is now open for the meeting, to be held Nov. 3-5 in New York. Be part of medical research's most forward-thinking, outcomes-oriented, and patient-focused event.
Find the latest news and resources on intellectual property
FasterCures' TRAIN (The Research Acceleration and Innovation Network) has debuted the Intellectual Property Intersection to serve as a base for increasing interaction and fostering relationships among emerging nonprofit disease groups, patient advocates, technology transfer professionals, and other stakeholders. The page features best practices, case studies, sample templates, relevant news, and more.
View archive of Webinar on LLS' Therapy Acceleration Program
FasterCures has long believed that philanthropy can be a significant force for progress in medical research, when applied strategically. In an extremely informative Webinar on June 19, participants heard about a terrific example of the strategic application of philanthropy at the Leukemia & Lymphoma Society (LLS) in its Therapy Acceleration Program. View the summary, slides, and archive.
Payor community partnerships take center stage
As a keynote speaker at America's Health Insurance Plans' Institute 2013, held June 12-14 in Las Vegas, Margaret Anderson, executive director of FasterCures, discussed accelerating disruptive innovation throughout healthcare. "Every second is urgent," Anderson told the health insurance leaders gathered for the talk. Anderson's remarks are explored in this blog from the Smartblog on Leadership.
- Participating organizations of FasterCures' TRAIN (The Research Acceleration and Innovation Network) are coming together with payors, product developers, providers, and government officials to discuss payor issues in-depth this week during a day-long workshop. Look for a summary of the discussion on tumblr and in next month's FasterCures Track newsletter.
Our goal: Increase patient engagement in research.
Advancing precision medicine to the clinic
It's a good sign of progress when the barriers for translational medicine seem to move toward the less complex – from the technological challenges to the logistical. Scientists can now access technology that allows them to perform cutting-edge molecular analysis on actual human biospecimens, regardless of their research institution. Read our blog on the promise of precision medicine.
Why does medical research matter to you? Share your story today
Add your story to the 120 that are a part of our Time=Lives campaign, which illustrates how saving time in medical research can save lives.
|Finding cures and meaningful treatment options for rare diseases is a cause Gene Williams cares deeply about both professionally and personally. He is both the chairman and CEO of DART Therapeutics as well as the father of a son with Duchenne muscular dystrophy, the most common fatal genetic disorder diagnosed in young boys.
|The patient is where it all begins and where it all ends," says Kim McCleary, a leader in the chronic fatigue immune dysfunction syndrome community and an advocate for a more patient-centered approach to healthcare and medical research.
|As vice president of public affairs at the Association of Clinical Research Organizations, John Lewis understands the importance of supporting medical research. "Ultimately we'll all be patients," he says.
Our goal: Facilitate greater access to and more strategic allocation of capital to support results-driven medical research.
Case studies explore novel approaches to drug development
Our Fixes in Financing series has now highlighted 10 case studies that help to address the need for novel approaches to early-stage drug development in the biopharmaceutical industry. The models include revolving funds, precompetitive alliances, independent nonprofits, and more.
Download a translational research resource, which includes the importance of translational research, the stages of medical research, and the players who are translating science into cures.
Did you know that every $1 invested in the Human Genome Project has triggered $178 in U.S. economic activity? Download and share striking graphics from United for Medical Research.